BioCardia Q2 FY26 net loss narrows to $1.61 million; cash rises to $4.12 million as of June 30, 2026

Reuters2026/08/12 20:13

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioCardia posted a net loss of $1.61 million in Q2 2026, narrowing from $2.05 million a year earlier.
Loss per share improved to $0.13 from $0.40 in the prior-year quarter.
Research and development expense fell to $893,000 from $1.37 million, due to closeout of the CardiAMP HF trial.
Cash and cash equivalents ended the quarter at $4.12 million; net proceeds of about $4.9 million were raised via an at-the-market facility.
Management cited PMDA support for a Q4 Shonin submission for CardiAMP, FDA feedback that CardiAMP HF II may support PMA, and potential De Novo Helix approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121605PRIMZONEFULLFEED9809004) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioCardia Q2 FY26 net loss narrows to $1.61 million; cash rises to $4.12 million as of June 30, 2026

You may also like

Crypto prices